Protease Inhibitor Research

General Issues

Researchers Uncover Insulin Resistance Link (November 24, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
ECG Abnormalities With PIs Versus NNRTIs in SMART Trial (September 13, 2010)
From National AIDS Treatment Advocacy Project
Protease Inhibitor-to-Isentress Switch Is Effective, Lipid Friendly (July 20, 2010)
From AIDSmeds.com
Trading a Ritonavir-Boosted PI for Twice-Daily Raltegravir in SPIRAL (July 19, 2010)
From National AIDS Treatment Advocacy Project
When HIV Regimens Fail, Resistance Risk Appears Higher on NNRTIs Than Protease Inhibitors (October 3, 2008)
From aidsmap.com
Regimens With Boosted Protease Inhibitors Are the Most Resistance-Proof, Study Finds (May 22, 2008)
In The Journal of Infectious Diseases
Protein Buildup May Be Linked to Fat Gain in HIVers on Protease Inhibitors, Researchers Say (July 18, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
HIV JournalView: Adherence, Viral Fitness and NNRTI and PI Resistance (February/March 2006)
Bangsberg et al find that NNRTIs are more likely to suppress HIV than a single PI, but are also more vulnerable to resistance at low adherence levels.
From The Body PRO
PI-Based Therapy Does Not Increase Glucose Intolerance, Gestational Diabetes in Pregnant, HIV-Infected Women (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
Pharmacokinetic Data Show That Fosamprenavir + Atazanavir Combination Should Not Be Used (February 6, 2006)
However, boosting with atazanavir instead of ritonavir does appear feasible, this study finds.
In The 13th Conference on Retroviruses and Opportunistic Infections
Dual-Boosted Protease Inhibitor Regimen Shows Promise, but How Will It Be Used? (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Protease Inhibitors Not Associated With Fat Gain; Some Antiretrovirals Can Cause Fat Loss, Study Says (November 3, 2005)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO
HIV JournalView: Carotid Intima-Media Thickness Not Associated With Protease Inhibitor Use (July/August 2005)
[Archived Article]
From The Body PRO
My Friend Ritonavir: The Concept of "Boosting" (December 2004)
[Archived Article]
This research update reviews what we know about boosting HAART regimens with ritonavir (free registration required).
In The PRN Notebook
Triple PI Therapy May Help Heavily Treatment-Experienced Patients, But Pill Burden a Concern (October 2004)
[Archived Article]
Quick recap of a study in JAIDS.
In HIV Treatment ALERTS!, from The Center for AIDS
Protease Inhibitors Appear More Likely to Cause Atherosclerosis Than NNRTIs (July 15, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
Confort Study Supports Switch From Protease Inhibitor to Nevirapine (July 14, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
NNRTI Resistance Occurs More Often at Lower Levels of Adherence Than Does PI Resistance (July 14, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
Tipranavir Reduces Concentrations of Other Protease Inhibitors (July 14, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
Drug Development News: Gilead (May/June 2004)
[Archived Article]
A new prodrug technology targeting lymphocytes could all but revolutionize protease inhibitor therapy.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Changes to Labeling for Desyrel (Trazodone Hydrochloride) Tablets (PDF) (May 2004)
[Archived Article]
A "Dear Healthcare Professional" letter on potential interactions between this antidepressant and CYP3A4 inhibitors such as indinavir and ritonavir.
From U.S. Food and Drug Administration
Protease Inhibitor Therapy: Boosted and Double-Boosted Options to the Fore (March 2004)
[Archived Article]
In The PRN Notebook
Triple-PI Regimens for Rescue Treatment (February 10, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Dual-PI Regimen Preferred Over Single-PI Regimen After Initial PI Failure (February 9, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Clinical Efficacy of Antiretroviral Combination Therapy Based on Protease Inhibitors or Non-Nucleoside Analogue Reverse Transcriptase Inhibitors: Indirect Comparison of Controlled Trials (January 31, 2004)
[Archived Article]
Three-drug regimens containing a protease inhibitor are found to more effectively suppress HIV than three-drug regimens containing NNRTIs.
In British Medical Journal
Endothelial Function in HIV-Infected Patients Receiving Protease Inhibitor Therapy: Does Immune Competence Affect Cardiovascular Risk? (November 2003)
[Archived Article]
Abstract of a study in the Quarterly Journal of Medicine.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Switching From PI to Nevirapine in Patients With Undetectable Viral Load Is Safe and Potent (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Association Between Protease Inhibitor Use and Increased Cardiovascular Risk in Patients Infected With Human Immunodeficiency Virus: A Systematic Review (September 12, 2003)
[Archived Article]
In Clinical Infectious Diseases
Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients With Human Immunodeficiency Virus Infection (September 11, 2003)
[Archived Article]
In The New England Journal of Medicine
Protease Inhibitors and Severe Adverse Events (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Switch to Nevirapine From Protease Inhibitor Lowers Triglycerides and Maintains Viral Load Suppression (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Better Suppression, Adherence With Once-Daily FTC/ddI/Efavirenz Than Most PI-Based Regimens (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Older PIs Linked to Early Coronary Artery Disease (April 7, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Protease Inhibitors and Atherosclerosis (January/February 2003)
[Archived Article]
In TAGline, from Treatment Action Group
Research From the 42nd ICAAC: Two PIs vs. Two PIs vs. Efavirenz (December 2002)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Immune Reconstitution Is Similar in Antiretroviral-Naive Subjects Following 1 Year of Therapy With a Triple NRTI-Based or Protease Inhibitor-Containing ARV Regimen (November 21, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
104 Weeks Outcome of Simplified Regimens in PI-Experienced Patients (November 19, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
Study Finds Protease Inhibitors May Help Cause Lipodystrophy (October 30, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Evaluation of Coronary Artery Calcification by Electron Beam Computed Tomography in HIV-Infected Men Receiving Prolonged Protease Inhibitor Therapy (October 26, 2002)
[Archived Article]
In 40th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
Study Examines Mortality Factors in HIV Patients on Protease Inhibitors (October 10, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Data From the 14th International AIDS Conference: Spare the PIs (October 2002)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Effect of Stavudine, Zidovudine and HIV Protease Inhibitor Therapy on Subcutaneous Leg Fat Wasting in HIV-Infected Males -- A Longitudinal Study (September 25, 2002)
[Archived Article]
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
Perspective of HIV-Associated Coronary Heart Disease (July 10, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
In Routine Practice, the Durability of First-Line HAART Is Better for NNRTI Than PI-Based Regimens, Regardless of Baseline HIV Status (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
Saquinavir With Low-Dose Ritonavir Twice Daily (May 9, 2002)
[Archived Article]
From Canadian AIDS Treatment Information Exchange
Quality of Life, Emotional Status, and Adherence of HIV-1-Infected Patients Treated With Efavirenz Versus Protease Inhibitor-Containing Regimens (April 15, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
A New Look at Liver Toxicity Development During Antiretroviral Therapy Containing Protease Inhibitors in Patients With HIV (March 11, 2002)
[Archived Article]
To read PDF, click here.
In STEP Ezine, from Seattle Treatment Education Project
Switching Protease Inhibitors to Nevirapine (NEV), Efavirenz (EFA) or Abacavir (ABA): A Randomized, Multicenter, Open-Label, Simplification Trial (February 28, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Molecular Mechanism of I50V, I54L and I54M Resistance to Amprenavir and Other HIV-1 Protease Inhibitors (February 26, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Distinguishable Lipid Profiles Between PI and NNRTI Therapy May Carry Different Risk of Cardiovascular Disease (CVD) (February 25, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
In Vitro Model for Antiviral Activity for Amprenavir (APV)/Ritonavir (RTV) (December 19, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Impact on Fitness Conferred by Amprenavir Resistance Mutations (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Variations in HIV-1 Gag p6 Contribute to the Amprenavir-Specific Protease I50V Resistance Pathway (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Virologic Response to Abacavir/Efavirenz/ddI + Hydroxyurea in Subjects Failing Initial NRTI + PI Therapy (NZTA4008 Study) (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Select HIV Protease Inhibitors Alter Bone and Fat Metabolism In Vitro (December 16, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Amprenavir (APV) Plasma and Intracellular Concentrations When Co-Administered With Ritonavir (RTV) in Twice- and Once-Daily Regimens in HIV-Infected Patients (December 16, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Protease Inhibitors in Children: Combination Therapy Reduced Death by Two Thirds (November 23, 2001)
[Archived Article]
To read PDF, click here.
In AIDS Treatment News, from AIDS Treatment News
The Impact of First Line Therapies on Lipid Metabolism: The FRAMS Data (October 28, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
A Retrospective Cohort Study of the Durability of Antiretroviral Therapy Using Nevirapine versus Antiretroviral Therapy Using Protease Inhibitors (October 27, 2001)
[Archived Article]
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
Simplification of Protease Inhibitor-Containing HAART Regimen With Abacavir Maintains Viral Suppression and Favorable Adherence in HIV-1 Infected Adults (October 27, 2001)
[Archived Article]
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
Comparison of QD Protease Inhibitors (PIs): Estimated Cmin/IC50 (IQ) After Missed Dose Shows Agenerase Advantage (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Experimental PI Drugs (Spring 2001)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
Do Protease Inhibitors Increase the Risk for Coronary Heart Disease Among HIV-Positive Patients-Follow-Up Through June 2000 (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Plasma Trough Levels Correlate with Distinct Genetic Mechanisms During the Development of Amprenavir Resistance (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Efficacy and Safety of Switch to 3TC 300 mg QD vs. Continued 3TC 150 mg BID in Subjects with Virologic Suppression on Stable 3TC/d4T/PI Therapy (COLA4005): Final 24-Week Results (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Incidence and Predictors of Clinical Progression Among HIV-Infected Patients Experiencing Virologic Failure of Protease Inhibitor-Based Regimens (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
More Data on the Comparative Efficacy of Protease Inhibitors Versus Non-nukes (October 10, 2000)
[Archived Article]
STEP's coverage of the 40th ICAAC Conference.
In STEP Ezine, from Seattle Treatment Education Project
New Protease Inhibitors (October 2000)
[Archived Article]
From Project Inform
Efficacy of Protease Inhibitor Switching to Nevirapine in Patients on HAART with Undetectable Viral Load (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
Sustained Virologic Suppression in Subjects Switched From Protease Inhibitors to Nevirapine (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
What's This About P-Glycoprotein? (July 2000)
[Archived Article]
In TAGline, from Treatment Action Group
Simpler Is Better, So Far (Winter 1999/2000)
[Archived Article]
To PI-spare or not to PI-spare. Can't we just call it a draw?.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Blood Lipid Treatment and Switching Drugs for Lipodystrophy (May 1999)
[Archived Article]
In Body Positive, from Body Positive
Treating Fat Redistribution Syndrome (April 22-25, 1999)
[Archived Article]
In The 3rd International Conference on Nutrition and HIV Infection, from The Body PRO
Growth Hormone (rhGH) and Fat Redistribution Syndrome (April 22-25, 1999)
[Archived Article]
In The 3rd International Conference on Nutrition and HIV Infection, from The Body PRO
Quantifying Abnormalities Associated with Fat Redistribution Syndrome (April 22-25, 1999)
[Archived Article]
In The 3rd International Conference on Nutrition and HIV Infection, from The Body PRO
The Changing Face of Malnutrition and HIV (April 22-25, 1999)
[Archived Article]
In The 3rd International Conference on Nutrition and HIV Infection, from The Body PRO
HAART, Dyslipidemia, and Hyperglycemia (April 22-25, 1999)
[Archived Article]
In The 3rd International Conference on Nutrition and HIV Infection, from The Body PRO
A Multi-Center, Randomized, Open-Label, Comparative Trial of the Clinical Benefit of Switching the Protease Inhibitor by Nevirapine in HAART-Experienced Patients Suffering Lipodystrophy (February 4, 1999)
[Archived Article]
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Avascular Necrosis in HIV-Infected Patients: A Potential Link to Protease Inhibitors (February 3, 1999)
[Archived Article]
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Mechanisms Responsible for Metabolic Complications of Antiretroviral Therapy (February 3, 1999)
[Archived Article]
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Co-Administration of Indinavir 1200 mg with Nelfinavir 1250 mg in a Twice Daily Regimen: Preliminary Safety, PK Activity (February 2, 1999)
[Archived Article]
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
The Trouble with Fat: Concerns Continue over the Cause and Treatment of Fat Redistribution Syndrome (February 1999)
[Archived Article]
From Seattle Treatment Education Project
Incidence of All New Clinical Events in Patients Started on HAART (November 14, 1998)
[Archived Article]
In The 36th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
Co-Administration of Indinavir 1,200 mg (IDV) and Nelfinavir (NFV) 1,250 mg in a Twice Daily Regimen: Preliminary Safety, Pharmacokinetic (PK) and Anti-Viral Activity (November 14, 1998)
[Archived Article]
In The 36th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
Successful Standard Treatment for Lipid Abnormalities (October 2, 1998)
[Archived Article]
From AIDS Treatment News
Incidence and Factors Associated with the Development of Hypercholesterolemia and Hyperglycemia in HIV-Infected Patients Using a Protease Inhibitor (September 26, 1998)
[Archived Article]
In The 38th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Gemfibrozil Effectively Lowers Protease-Associated Hypertriglyceridemia in HIV-Infected Patients (September 25, 1998)
[Archived Article]
In The 38th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Protease Inhibitors and Reconstitution of the Immune System (August 1998)
[Archived Article]
In HIV Newsline, from San Francisco General Hospital
Protease Inhibitor-Associated Hyperglycemia: Results of Switching from Indinavir to Nelfinavir (July 1, 1998)
[Archived Article]
In The 12th International AIDS Conference, from The Body PRO
What Have We Learned About Lipodystrophy, High Cholesterol, Diabetes, and Long Term Complications of Protease Inhibitors? (June 29 and 30, July 1, 1998)
[Archived Article]
In The 12th International AIDS Conference, from The Body PRO
Double Protease Inhibitor Combinations (April 1998)
[Archived Article]
In Project Inform Perspective
Antiretroviral Therapy: Unique Adverse Effects of Protease Inhibitors (February 3, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Advances Made Towards Simpler Protease Inhibitor Regimens (February 3, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Maintaining Protease Inhibitor Therapy Setting (February 2, 1998)
[Archived Article]
From Seattle Treatment Education Project
Double Protease Inhibitor Combinations (September 28-October 1, 1997)
[Archived Article]
In The 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Half-full or Half-empty: No Simple Answer on Protease Inhibitor Failure (October 1997)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
Metabolic Disturbances in HIV Infection Find Friend Not Foe in Protease Inhibitor Regimens (August 1997)
[Archived Article]
In TAGline, from Treatment Action Group
Protease Inhibitors: Major Study Stopped When 3-Drug Arm Proves Superior (March 7, 1997)
[Archived Article]
From AIDS Treatment News
Triple Combination Therapy Including Indinavir Is Effective in Advanced AIDS (January 1997)
[Archived Article]
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Protease Combinations May Be the Most Effective (January 1997)
[Archived Article]
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Consensus Statement on the Further Development of Protease Inhibitors and Human Growth Hormone (March 15, 1996)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News